玛雅吧
中
中文
English
About Us
About Us
Awards
Development Milestones
Our Culture
Social responsibility
Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
News
Company News
Media Focus
With the objective of 'creating excellence in China's pharmaceuticals and add momentum to "Made in China"',Hansoh endeavors to make its own contribution to the “Healthy China 2030” master plan.
With the objective of 'creating excellence in China's pharmaceuticals and add momentum to "Made in China"',Hansoh endeavors to make its own contribution to the “Healthy China 2030” master plan.
Products
CNS Diseases
Oncology
Anti-infectives
Diabetes
Gastrointestinal
Cardiovascular
Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
R&D
R&D System
R&D Platform
R&D Achievements
National-level R&D Designations
Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
Services
Marketing Network
Information Inquiry
International Market
Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate
Contact Us
Talent Development
Social Recruitment
Campus Recruitment
Staff Snapshot
Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
搜索
News
locations:
Home
−
News
−
Company News
Company News
Media Focus
2024 AACR | Hansoh Pharma Presents Clinical Data on HS-10370 Phase I Study at AACR Annual Meeting
The 115th Annual Meeting of the American Associati……
2024-04-12
ELCC 2024 | Six Innovations on Aumolertinib, Originally Developed by Hansoh Pharma, Selected for International Academic Assembly
The European Lung Cancer Congress (ELCC 2024) will……
2024-03-21
2023 IDF | Hansoh Pharma Release the Phase 1 Study Data of t a Dual GIP and GLP-1 Receptor Agonist
The IDF Virtual Congress 2023 will be held from De……
2023-12-11
2024
04-01
“Expert Recommendations on the Clinical Practice of Treating NMOSD With Inebilizumab” Released in Shanghai
Recently, the 4th Annual Academic Meeting of the Shanghai Stroke Association and the 17th Chinese Neurology Forum were held in Shanghai, where the “Ex...
Read more
2023
11-20
Holding the Lead! Hansoh Pharma Maintains Third Place as "Best Industrial Enterprise for Pharmaceutical R&D Product Line in China"
On November 18, the 2023 (40th) China Pharmaceutical Industry Information Annual Conference was officially launched in Beijing, where the highly antic...
Read more
2023
11-20
2023 ASH|Hansoh Pharma Set to Release Four Study Results on Flumatinib at Prestigious International Hematology Event
Recently, the 65th ASH Annual Meeting and Exposition announced the papers and reports to be represented at this year's event, among which four study r...
Read more
2023
11-08
Hansoh Pharma's CMO, Professor Wu Qiong, Attends 2023 CHSESI
The 15th China Healthcare Summit of Entrepreneurs, Scientists and Investors (CHSESI), hosted by the China Pharmaceutical Enterprises Association, Chin...
Read more
2023
11-03
Widely Acclaimed | Study Results on Sheng Luo Lai® from Hansoh Pharma Published in eClinicalMedicine From World-Leading Lancet Journals
On October 28, eClinicalMedicine (IF:15.1), from top global medical journal group The Lancet, released its phase III clinical research paper on Sheng ...
Read more
2023
10-18
Hansoh Pharma's Ameile Patent Wins China Patent Gold Award at the 24th WIPO-CNIPA Awards for Chinese Outstanding Patented Inventions
The 24th WIPO-CNIPA Awards for Chinese Outstanding Patented Inventions was held in Dalian in Northeast China on October 14. Hansoh Pharma's Ameile pat...
Read more
2023
08-08
WCLC 2023 | Hansoh Pharma's AMEILE (Aumolertinib) is to Present 42 Innovative Research at the International Academic Conference
The IASLC 2023 World Conference on Lung Cancer (WCLC) is scheduled to be held in Singapore from September 9 - 12, 2023. During this conference, Hansoh...
Read more
2023
08-07
Hansoh Pharma releases key data for Saint Luolai®, introducing a safe and long-lasting innovative drug to CKD patients with renal anemia
Recently, during the 2023 Annual Conference of the Chinese Nephrologist Association (CNA), the "First National Medical Information Publication of Pegm...
Read more
1
2
3
4
5
...
18
19
Next page